At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Placebo formulated with HFA-152a propellant via pMDI +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Randomised, Controlled, 2-way Cross-over Study to Assess the Effect of Multiple Doses of the New HFA-152a Propellant Versus the Marketed HFA-134a Propellant on Mucociliary Clearance in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Placebo formulated with HFA-152a propellant via pMDI and Placebo formulated with HFA-134a propellant via pMDI for Mucociliary Clearance. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The primary objective of this study was to assess the effect of multiple doses of the HFA-152a propellant and the HFA-134a propellant on mucociliary clearance (MCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMucociliary Clearance
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedMay 2023
Enrollment StartJun 2023
Primary CompletionSep 2023
TodayJul 2026
First PostedMay 25, 2023
Enrollment StartJun 26, 2023
Primary CompletionSep 8, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.1 years ago
Interventions
Placebo formulated with HFA-152a propellant via pMDIother
5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
Placebo formulated with HFA-134a propellant via pMDIother
5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8